Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New Generation Gepants: Migraine Acute and Preventive Medications
David Moreno‐Ajona, María Dolores Villar‐Martínez, Peter J. Goadsby
Journal of Clinical Medicine (2022) Vol. 11, Iss. 6, pp. 1656-1656
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Andrew F. Russo, Debbie L. Hay
Physiological Reviews (2022) Vol. 103, Iss. 2, pp. 1565-1644
Open Access | Times Cited: 162
Migraine: from pathophysiology to treatment
Francesca Puledda, Elisa Silva, Kanokrat Suwanlaong, et al.
Journal of Neurology (2023) Vol. 270, Iss. 7, pp. 3654-3666
Open Access | Times Cited: 82
Shared and independent roles of CGRP and PACAP in migraine pathophysiology
Adisa Kuburas, Andrew F. Russo
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 50
Gepants for Acute and Preventive Migraine Treatment: A Narrative Review
Jamir Pitton Rissardo, Ana Letícia Fornari Caprara
Brain Sciences (2022) Vol. 12, Iss. 12, pp. 1612-1612
Open Access | Times Cited: 39
Mode and site of action of therapies targeting CGRP signaling
Alejandro Labastida‐Ramírez, Edoardo Caronna, Cédric Gollion, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 33
Future targets for migraine treatment beyond CGRP
Linda Al‐Hassany, Deirdre M. Boucherie, Hannah Creeney, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 29
Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis
Cristina Tassorelli, Kateryna Onishchenko, Rashmi B. Halker Singh, et al.
Cephalalgia (2024) Vol. 44, Iss. 2
Open Access | Times Cited: 10
Influence of metabolic state and body composition on the action of pharmacological treatment of migraine
Noor Bruijn, Romy van Lohuizen, Malgorzata Boron, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 10
Antagonism of CGRP Receptor: Central and Peripheral Mechanisms and Mediators in an Animal Model of Chronic Migraine
Rosaria Greco, Chiara Demartini, Miriam Francavilla, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3092-3092
Open Access | Times Cited: 33
Unmet Needs in the Acute Treatment of Migraine
Enrico Bentivegna, Silvia Galastri, Dilara Onan, et al.
Advances in Therapy (2023) Vol. 41, Iss. 1, pp. 1-13
Open Access | Times Cited: 14
Concomitant medications, functional foods, and supplements: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
Justin Tondt, Harold Bays
Obesity Pillars (2022) Vol. 2, pp. 100017-100017
Open Access | Times Cited: 19
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials
Marcello Silvestro, Ilaria Orologio, Mattia Siciliano, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 2, pp. 79-96
Closed Access | Times Cited: 11
Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine
William Wells-Gatnik, Lanfranco Pellesi, Paolo Martelletti
Expert Review of Neurotherapeutics (2024), pp. 1-11
Closed Access | Times Cited: 4
US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review
Patrick Eugeni, Megan Rooney, Nicolas Saikali, et al.
Advances in Therapy (2025) Vol. 42, Iss. 2, pp. 1207-1221
Open Access
Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives
Jan Versijpt, Koen Paemeleire, Uwe Reuter, et al.
The Lancet (2025) Vol. 405, Iss. 10483, pp. 1014-1026
Closed Access
Overcoming obstacles to effective treatment of patients with migraine (Statement of the expert group on optimizing treatment of patients with migraine)
Г. Р. Табеева, А. Р. Артеменко, M. I. Koreshkina, et al.
Neurology neuropsychiatry Psychosomatics (2025) Vol. 17, Iss. 2, pp. 4-14
Open Access
The Utility of a Novel, Combined Biofeedback-Virtual Reality Device as Add-on Treatment for Chronic Migraine
Ami Cuneo, Robin Yang, Haoran Zhou, et al.
Clinical Journal of Pain (2023) Vol. 39, Iss. 6, pp. 286-296
Closed Access | Times Cited: 10
Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response
Gabriella Juhász, Kinga Gecse, Dániel Baksa
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108523-108523
Open Access | Times Cited: 10
Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study)
Luigi Francesco Iannone, Gloria Vaghi, Gabriele Sebastianelli, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Evidence-based guidelines for the pharmacological treatment of migraine
Raffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, et al.
Cephalalgia (2025) Vol. 45, Iss. 4
Closed Access
Calcitonin Gene-Related Peptide Systemic Effects: Embracing the Complexity of Its Biological Roles—A Narrative Review
Adriano Bonura, Nicoletta Brunelli, Marilena Marcosano, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13979-13979
Open Access | Times Cited: 9
What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
Marta Waliszewska‐Prosół, Doğa Vurallı, Paolo Martelletti
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
A Review of Calcitonin Gene-Related Peptide and Its Implications for Vestibular Disorders
R L Baron, Kristen K. Steenerson
Current Treatment Options in Neurology (2024) Vol. 26, Iss. 6, pp. 203-228
Closed Access | Times Cited: 2
Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment
Rajinder Bhardwaj, Mary Donohue, Jennifer Madonia, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 7
Open Access | Times Cited: 2
The sympathetic nervous system shapes the tumor microenvironment to impair chemotherapy response
Annabel V Manoleras, Erica K. Sloan, Aeson Chang
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top